Genetic markers and traditional risk factors in predicting atrial fibrillation in patients with arterial hypertension, focus on the renin-angiotensin-aldosterone system genes

Abstract

BACKGROUND: Genetic and environmental factors are involved in the development of atrial fibrillation in arterial hypertension. This determines the relevance of studying gene-environment interactions in the occurrence of arrhythmia.

AIM: To evaluate the contribution of the renin-angiotensin-aldosterone system genes polymorphisms to the susceptibility to atrial fibrillation in patients with arterial hypertension, and also to study the combined influence of these polymorphisms and environmental factors on the risk of arrhythmia.

MATERIALS AND METHODS: The study included 60 patients with arterial hypertension and paroxysmal atrial fibrillation (study group), 60 patients with arterial hypertension without atrial fibrillation (comparison group-1) and 20 healthy volunteers (comparison group-2). Angiotensin-converting enzyme (ACE (I/D)) and angiotensin II type 1 receptor gene (AGTR1 (A1166C)) polymorphisms were analyzed by real-time polymerase chain reaction.

RESULTS: Genotype II and allele I of the ACE gene (I/D) in patients with arterial hypertension and atrial fibrillation were significantly more frequent compared to patients with arterial hypertension without arrhythmia (χ² = 4.547; p = 0.03 and χ² = 4.818; p = 0.03 respectively). Carriage of genotype II in patients with arterial hypertension increased the chance of developing atrial fibrillation by 2.8 times (95% CI 1.19–7.18). The odds ratio (OR) for arrythmia development in patients with arterial hypertension and allele I was 1.8 (95% CI 1.10–3.07). The presence of obesity in patients with arterial hypertension in the presence of genotype II of the ACE gene (I/D) was associated with an increased risk of developing atrial fibrillation, compared with the genotype alone (OR = 4.16, 95% CI 1.16–19.87). A study of the A1166C polymorphism of the AGTR1 gene did not reveal a reliable significant relationship between its inheritance and the development of atrial fibrillation.

CONCLUSION: Genotype II and allele I of the ACE gene (I/D) were statistically significantly more frequent in patients with arterial hypertension and atrial fibrillation. Carriage of genotype II and allele I of the ACE gene (I/D) increased the chance of developing atrial fibrillation in patients with arterial hypertension. Obesity had a significant effect on the susceptibility to atrial fibrillation in the presence of genotype II of the ACE gene (I/D) in hypertensive patients.

Keywords

atrial fibrillation / arterial hypertension / renin-angiotensin-aldosterone system / gene polymorphism / risk factor / obesity

References

[1] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Russian Journal of Cardiology. 2021;26(9):4701. EDN: NNLETB doi: 10.15829/1560-4071-2021-4701

[2] Hindricks G., Potpara T., Dagres N., и др. Рекомендации ESC2020 по диагностике и лечению пациентов с фибрилляцией предсердий, разработанные совместно с Европейской ассоциацией кардиоторакальной хирургии (EACTS) // Российский кардиологический журнал. 2021. Т. 26, № 9. ID 4701. EDN: NNLETB doi: 10.15829/1560-4071-2021-4701

[3] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Russian Journal of Cardiology. 2021;26(9):4701. EDN: NNLETB doi: 10.15829/1560-4071-2021-4701

[4] Ionin VA, Barashkova EI, Filatova AG, et al. Atrial fibrillation in St Petersburg cohort: frequency, risk factors, antiarrhythmic therapy and thromboembolism prevention. Arterial Hypertension. 2020;26(2):192–201. EDN: NFGHBI doi: 10.18705/1607-419X-2020-26-2-192-201

[5] Ионин В.А., Барашкова Е.И., Филатова А.Г., и др. Фибрилляция предсердий в когорте амбулаторных пациентов Санкт-Петербурга: встречаемость, факторы риска, антиаритмическая терапия и профилактика тромбоэмболических осложнений // Артериальная гипертензия. 2020. Т. 26, № 2. С. 192–201. EDN: NFGHBI doi: 10.18705/1607-419X-2020-26-2-192-201

[6] Ionin VA, Barashkova EI, Filatova AG, et al. Atrial fibrillation in St Petersburg cohort: frequency, risk factors, antiarrhythmic therapy and thromboembolism prevention. Arterial Hypertension. 2020;26(2):192–201. EDN: NFGHBI doi: 10.18705/1607-419X-2020-26-2-192-201

[7] Akhyt BA, Kozhabekova BN, Urazalina SZh, et al. The prevalence of risk factors for the development of atrial fibrillation among people of Kazakh nationality. Medicine (Almaty). 2019;(7-8):10–17. EDN: ZMCGIM doi: 10.31082/1728-452X-2019-205-206-7-8-10-17

[8] Ахыт Б.А., Кожабекова Б.Н., Уразалина С.Ж., и др. Распространенность факторов риска развития фибрилляции предсердий среди лиц казахской национальности // Медицина (Алматы). 2019. № 7–8. С. 10–17. EDN: ZMCGIM doi: 10.31082/1728-452X-2019-205-206-7-8-10-17

[9] Akhyt BA, Kozhabekova BN, Urazalina SZh, et al. The prevalence of risk factors for the development of atrial fibrillation among people of Kazakh nationality. Medicine (Almaty). 2019;(7-8):10–17. EDN: ZMCGIM doi: 10.31082/1728-452X-2019-205-206-7-8-10-17

[10] Wanahita N, Messerli FH, Bangalore S, et al. Atrial fibrillation and obesity — results of a meta-analysis. Am Heart J. 2008;155(2): 310–315. doi: 10.1016/j.ahj.2007.10.004

[11] Wanahita N., Messerli F.H., Bangalore S., et al. Atrial fibrillation and obesity — results of a meta-analysis // Am Heart J. 2008. Vol. 155, N. 2. P. 310–315. doi: 10.1016/j.ahj.2007.10.004

[12] Wanahita N, Messerli FH, Bangalore S, et al. Atrial fibrillation and obesity — results of a meta-analysis. Am Heart J. 2008;155(2): 310–315. doi: 10.1016/j.ahj.2007.10.004

[13] Tlegenova ZhSh, Zholdin BK, Kudaiberdieva GZ, Abdrakhmanov AS. Factors associated with atrial fibrillation in patients with hypertension and preserved left ventricle systolic function. Kardiologiia. 2019;59(5S):37–46. EDN: RLTEMJ doi: 10.18087/cardio.2617

[14] Тлегенова Ж.Ш., Жолдин Б.К., Кудайбердиева Г.З., Аббрахманов А.С. Факторы риска развития фибрилляции предсердий у больных артериальной гипертензией с сохраненной систолической функцией левого желудочка // Кардиология. 2019. Т. 5, № S5. С. 44–54. EDN: RLTEMJ doi: 10.18087/cardio.2617

[15] Tlegenova ZhSh, Zholdin BK, Kudaiberdieva GZ, Abdrakhmanov AS. Factors associated with atrial fibrillation in patients with hypertension and preserved left ventricle systolic function. Kardiologiia. 2019;59(5S):37–46. EDN: RLTEMJ doi: 10.18087/cardio.2617

[16] Staerk L, Sherer JA, Ko D, et al. Atrial fibrillation: Epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120(9): 1501–1517. doi: 10.1161/CIRCRESAHA.117.309732

[17] Staerk L., Sherer J.A., Ko D., et al. Atrial fibrillation: Epidemiology, pathophysiology, and clinical outcomes // Circ Res. 2017. Vol. 120, N. 9. P. 1501–1517. doi: 10.1161/CIRCRESAHA.117.309732

[18] Staerk L, Sherer JA, Ko D, et al. Atrial fibrillation: Epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120(9): 1501–1517. doi: 10.1161/CIRCRESAHA.117.309732

[19] Menezes AR, Lavie CJ, DiNicolantonio JJ, et al. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc. 2013;88(4):394–409. doi: 10.1016/j.mayocp.2013.01.022

[20] Menezes A.R., Lavie C.J., DiNicolantonio J.J., et al. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies // Mayo Clin Proc. 2013. Vol. 88, N. 4. P. 394–409. doi: 10.1016/j.mayocp.2013.01.022

[21] Menezes AR, Lavie CJ, DiNicolantonio JJ, et al. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc. 2013;88(4):394–409. doi: 10.1016/j.mayocp.2013.01.022

[22] Zhang C-H, Huang D-S, Shen D, et al. Association between serum uric acid levels and atrial fibrillation risk. Cell Physiol Biochem. 2016;38(4):1589–1595. doi: 10.1159/000443099

[23] Zhang C.-H., Huang D.-S., Shen D., et al. Association between serum uric acid levels and atrial fibrillation risk // Cell Physiol Biochem. 2016. Vol. 38, N. 4. P. 1589–1595. doi: 10.1159/000443099

[24] Zhang C-H, Huang D-S, Shen D, et al. Association between serum uric acid levels and atrial fibrillation risk. Cell Physiol Biochem. 2016;38(4):1589–1595. doi: 10.1159/000443099

[25] Bukvalnaya NV, Yakubova LV, Snezhitskiy VA. Arterial hypertension and atrial fibrillation: molecular genetic aspects of pathogenesis and complex therapy, focus on the renin-angiotensin-aldosterone system. Emergency cardiology and cardiovascular risks. 2020;4(2):986–993. EDN: YXRRHN doi: 10.51922/2616-633X.2020.4.2.986

[26] Буквальная Н.В., Якубова Л.В., Снежицкий В.А. Артериальная гипертензия и фибрилляция предсердий: молекулярно-генетические аспекты патогенеза и комплексной терапии, фокус на ренин-ангиотензин-альдостероновую систему // Неотложная кардиология и кардиоваскулярные риски. 2020. Т. 4, № 2. С. 986–993. EDN: YXRRHN doi: 10.51922/2616-633X.2020.4.2.986

[27] Bukvalnaya NV, Yakubova LV, Snezhitskiy VA. Arterial hypertension and atrial fibrillation: molecular genetic aspects of pathogenesis and complex therapy, focus on the renin-angiotensin-aldosterone system. Emergency cardiology and cardiovascular risks. 2020;4(2):986–993. EDN: YXRRHN doi: 10.51922/2616-633X.2020.4.2.986

[28] The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society ofHypertension (ESH) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Russian Journal of Cardiology. 2018;23(12):143–228. EDN: SLRUJJ doi: 10.15829/1560-4071-2018-12-143-228

[29] 2018 ЕОК/ЕОАГ рекомендации по лечению больных с артериальной гипертензией // Российский кардиологический журнал. 2018. Т. 23, № 12. С. 143–228. EDN: SLRUJJ doi: 10.15829/1560-4071-2018-12-143-228

[30] The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society ofHypertension (ESH) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Russian Journal of Cardiology. 2018;23(12):143–228. EDN: SLRUJJ doi: 10.15829/1560-4071-2018-12-143-228

[31] Gouissem I, Midani F, Soualmia H, et al. Contribution of the ACE (rs1799752) and CYP11B2 (rs1799998) gene polymorphisms to atrial fibrillation in the Tunisian population. Biol Res Nurs. 2022;24(1): 31–39. doi: 10.h1177/10998004211029376

[32] Gouissem I., Midani F., Soualmia H., et al. Contribution of the ACE (rs1799752) and CYP11B2 (rs1799998) gene polymorphisms to atrial fibrillation in the Tunisian population // Biol Res Nurs. 2022. Vol. 24, N. 1. P. 31–39. doi: 10.h1177/10998004211029376

[33] Gouissem I, Midani F, Soualmia H, et al. Contribution of the ACE (rs1799752) and CYP11B2 (rs1799998) gene polymorphisms to atrial fibrillation in the Tunisian population. Biol Res Nurs. 2022;24(1): 31–39. doi: 10.h1177/10998004211029376

[34] Ma R, Li X, Su G, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphisms associated with risk of atrial fibrillation: A meta-analysis of 23 case-control studies. J Renin Angiotensin Aldosterone Syst. 2015;16(4):793–800. doi: 10.1177/1470320315587179

[35] Ma R., Li X., Su G., et al. Angiotensin-converting enzyme insertion/deletion gene polymorphisms associated with risk of atrial fibrillation: A meta-analysis of 23 case-control studies // J Renin Angiotensin Aldosterone Syst. 2015. Vol. 16, N. 4. P. 793–800. doi: 10.1177/1470320315587179

[36] Ma R, Li X, Su G, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphisms associated with risk of atrial fibrillation: A meta-analysis of 23 case-control studies. J Renin Angiotensin Aldosterone Syst. 2015;16(4):793–800. doi: 10.1177/1470320315587179

[37] Kuskaeva AV, Niculina SU, Chernova AA, et al. The role of the I/D polymorphism of the ACE gene in the development of atrial fibrillation. Kardiologiia. 2018;58(2):5–9. EDN: YODGGM doi: 10.18087/cardio.2018.2.10079

[38] Кускаева А.В., Никулина С.Ю., Чернова А.А., и др. Роль полиморфизма I/D гена ACE в развитии фибрилляции предсердий // Кардиология. 2018. Т. 58, № 2. С. 5–9. EDN: YODGGM doi: 10.18087/cardio.2018.2.10079

[39] Kuskaeva AV, Niculina SU, Chernova AA, et al. The role of the I/D polymorphism of the ACE gene in the development of atrial fibrillation. Kardiologiia. 2018;58(2):5–9. EDN: YODGGM doi: 10.18087/cardio.2018.2.10079

[40] Kuskaeva AV, Nikulina SY, Chernova AA, et al. Role of AGTR1 A/C polymorphism in the development of atrial fibrillation. Therapeutic archive. 2017;89(9):48–52. EDN: WYKFQS doi: 10.17116/terarkh201789948-52

[41] Кускаева А.В., Никулина С.Ю., Чернова А.А., и др. Роль полиморфизма A/C гена AGTR1 в развитии фибрилляции предсердий // Терапевтический архив. 2017. Т. 89, № 9. С. 48–52. EDN: WYKFQS doi: 10.17116/terarkh201789948-52

[42] Kuskaeva AV, Nikulina SY, Chernova AA, et al. Role of AGTR1 A/C polymorphism in the development of atrial fibrillation. Therapeutic archive. 2017;89(9):48–52. EDN: WYKFQS doi: 10.17116/terarkh201789948-52

[43] Hou S, Lu Y, Huang D, et al. Association of atrial fibrillation with gene polymorphisms of connexin 40 and angiotensin II receptor type 1 in Chongming adults of Shanghai. Int J Clin Exp Med. 2015;15(7):11803–11810.

[44] Hou S., Lu Y., Huang D., et al. Association of atrial fibrillation with gene polymorphisms of connexin 40 and angiotensin II receptor type 1 in Chongming adults of Shanghai // Int J Clin Exp Med. 2015. Vol. 15, N. 7. P. 11803–11810.

[45] Hou S, Lu Y, Huang D, et al. Association of atrial fibrillation with gene polymorphisms of connexin 40 and angiotensin II receptor type 1 in Chongming adults of Shanghai. Int J Clin Exp Med. 2015;15(7):11803–11810.

[46] Bazhenova EA, Belyaeva OD, Berezina AV, et al. Renin-angiotensin-aldosterone system in patients with abdominal obesity and arterial hypertension. Arterial Hypertension. 2013;19(5):389–396. EDN: RRPWOT doi: 10.18705/1607-419X-2013-19-5-389-396

[47] Баженова Е.А., Беляева О.Д., Березина А.В., и др. Ренин-ангиотензин-альдостероновая система у больных абдоминальным ожирением и артериальной гипертензией // Артериальная гипертензия. 2013. Т. 19, № 5. C. 389–396. EDN: RRPWOT doi: 10.18705/1607-419X-2013-19-5-389-396

[48] Bazhenova EA, Belyaeva OD, Berezina AV, et al. Renin-angiotensin-aldosterone system in patients with abdominal obesity and arterial hypertension. Arterial Hypertension. 2013;19(5):389–396. EDN: RRPWOT doi: 10.18705/1607-419X-2013-19-5-389-396

RIGHTS & PERMISSIONS

Eco-Vector